

Global Anti-Parkinson Drugs Market Trends, Strategies, Opportunities For 2022-2026

The Business Research Company's Anti-Parkinson Drugs Global Market Report 2022 - Market Size, Trends, And Global Forecast 2022-2026

LONDON, GREATER LONDON, UK,
March 25, 2022 /EINPresswire.com/ --

According to '[Anti-Parkinson Drugs Global Market Report 2022](#) - Market Size, Trends, And Global Forecast 2022-

2026' published by The Business Research Company, the anti-parkinson drugs market size is expected to grow from \$8.86 billion in 2021 to \$9.56 billion in 2022 at a compound annual growth rate (CAGR) of 7.9%. The growth in the market is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. As per TBRC's anti-parkinson drugs market research the market size is expected to reach \$12.25 billion in 2026 at a CAGR of 6.4%. The increasing geriatric population and surging cases of Parkinson's disease (PD) are projected to drive the anti-parkinson drugs market growth.

Want to learn more on the anti-parkinson drugs market growth? Request for a Sample now:

<https://www.thebusinessresearchcompany.com/sample.aspx?id=3462&type=smp>

The anti-Parkinson drugs market consists of sales of drugs used for treating Parkinson's disease (PD), generated by the establishments that manufacture these drugs. Parkinson's disease is a neurodegenerative disorder that affects predominately dopaminergic neurons in a specific area of the brain named substantia nigra and disturbs the movement of the body. People suffering from PD may experience tremor, bradykinesia, limb rigidity, gait, and balance problems.

[Global Anti-Parkinson Drugs Market Trends](#)

Increasing investments by governments and companies for Parkinson's disease drug R&D is a major trend in the anti-Parkinson drugs market.

The global anti-Parkinson drugs market is segmented:

The Business
Research Company

Anti-Parkinson Drugs Global Market Report 2022 -
Market Size, Trends, And Global Forecast 2022-2026



By Drugs Class: Levodopa/Carbidopa, Dopamine Receptor Agonists, Monoamine Oxidase Type B (MAO-B) Inhibitors, Catechol-O-Methyltransferase (COMT)-inhibitors, Anticholinergics, Others
By Route of Administration: Oral, Injection, Transdermal
By Distribution Channel: Hospital Pharmacies, Retailer Pharmacies, Online Pharmacies
By Geography: The global anti-Parkinson's market is segmented into North America, South America, Asia-Pacific, Eastern Europe, Western Europe, Middle East and Africa. Among these regions, North America accounts for the largest share.

Read more on the global anti-parkinson drugs market report at:

<https://www.thebusinessresearchcompany.com/report/anti-parkinson-drugs-global-market-report>

Anti-Parkinson Drugs Global Market Report 2022 is one of a series of new reports from The Business Research Company that provides anti-parkinson drugs global market overviews, anti-parkinson drugs global market analysis and forecasts market size and growth for the global anti-parkinson drugs market, anti-parkinson drugs global market share, anti-parkinson drugs global market segments and geographies, anti-parkinson drugs global market players, anti-parkinson drugs global market leading competitor revenues, profiles and market shares. The anti-parkinson drugs market report identifies top countries and segments for opportunities and strategies based on market trends and key competitors' approaches.

TBRC's Anti-Parkinson Drugs Global Market Report 2022 includes information on the following:

Data Segmentations: Market Size, Global, By Region and Country, Historic and Forecast, and Growth Rates for 60 Geographies

Key Market Players: GlaxoSmithKline plc, Pfizer, Merck, Novartis, Roche, UCB S.A, Teva Pharmaceuticals, AbbVie Inc., Mylan, Boehringer Ingelheim, Orion Pharma, ACADIA Pharmaceuticals Inc, Sun Pharma, Wockhardt, Dr. Reddy's, Intas, US WorldMeds, Zydus Cadila, Cipla, Strides, 1 A Pharma, Upsher-Smith, Lundbeck, Vertical Pharmaceuticals, LLC, Zambon Pharmaceuticals, M Somerset Pharmaceuticals Inc., and Wockhardt.

Regions: Asia-Pacific, China, Western Europe, Eastern Europe, North America, USA, South America, Middle East and Africa.

Countries: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

And so much more.

Looking for something else? Here is a list of similar reports by The Business Research Company:

Neurodegenerative Disorder Therapeutics Global Market Report 2022

<https://www.thebusinessresearchcompany.com/report/neurodegenerative-disorder-therapeutic->

[global-market-report](#)

Multiple Sclerosis Drugs Global Market Report 2022

<https://www.thebusinessresearchcompany.com/report/multiple-sclerosis-drugs-global-market-report>

Central Nervous System Drugs Global Market Report 2022

<https://www.thebusinessresearchcompany.com/report/central-nervous-system-drug-global-market-report>

About [The Business Research Company?](#)

The Business Research Company has published over 1000 industry reports, covering over 2500 market segments and 60 geographies. The reports draw on 150,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders. The reports are updated with a detailed analysis of the impact of COVID-19 on various markets.

Check out our:

LinkedIn: <https://bit.ly/3b7850r>

Twitter: <https://bit.ly/3b1rmjS>

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxICpgmyFQ

Blog: <http://blog.tbrc.info/>

Oliver Guirdham

The Business Research Company

+44 20 7193 0708

info@tbrc.info

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/566533094>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2022 IPD Group, Inc. All Right Reserved.